Early Access — free while we kick the tires
EdgarHawk

Giraudo Bryan

COO/CFO

Director Officer

Latest: Director selling · May 2026

2 filings analyzed · 2 companies · Latest 2026-05-11

Companies

Company Buys Sells Direction
Protagonist Therapeutics, Inc PTGX 0 6 Net selling
Gossamer Bio, Inc. GOSS 1 0 Net buying

Activity

May 2026
medium
Sell
59,130 shares
$5,918,880
Significance 5/10

Director Bryan Giraudo sells nearly $6M in PTGX stock while simultaneously exercising $238K in options—mixed signal from a board member with a strong buy-timing track record.

Director Bryan Giraudo exercised options to acquire 36,000 shares but then immediately sold 59,130 shares over two days, netting a disposition of roughly 23,000 shares worth nearly $6M. This two-sided transaction is contradictory: the option exercise suggests some conviction in the company's direction, yet the rapid and much larger sale signals a reduction in his equity exposure. Giraudo's prior trades show a strong history of well-timed purchases, with prior buys consistently delivering positive returns—yet this filing reverses that pattern by shifting to net seller status. The company's fundamentals are challenged, showing significant revenue contraction and a net loss, which provides some rationale for liquidating shares. Giraudo's placement of large sales on the open market after exercising newly-vested options suggests he may be executing a planned divestiture rather than responding to immediate price movement, especially given that the stock is trading only slightly below its 52-week high.

June 2024
2024-06-20 Gossamer Bio, Inc. GOSS
high
Buy
100,000 shares
$59,110
Significance 6/10

COO/CFO Bryan Giraudo buys 100,000 GOSS shares at $0.59; stock now $0.57, down 57.8% in 90 days amid -$41.9M net loss.

Bryan Giraudo, COO/CFO of Gossamer Bio, purchased 100,000 shares at $0.59 on 2024-06-18, increasing his holdings from 380,010 to 480,010 shares (a 26.3% increase in position size). The stock has since declined to $0.57, down 57.8% over the past 90 days and 68.7% from its 52-week high of $1.82, despite Giraudo's prior buy at GOSS on 2023-11-13 returning +54.2% over 90 days. The company is unprofitable, with net income of $-41.9M, yet the CFO has committed to further accumulation at depressed levels. This marks a material insider commitment despite severe price deterioration and negative fundamentals, warranting scrutiny into whether this reflects confidence in a turnaround or execution challenges that the C-suite has not yet publicly disclosed.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access